{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977333",
  "id": "02977333",
  "pages": 21,
  "price_sensitive": true,
  "date": "20250806",
  "time": "0829",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250806/pdf/06ml1j2n9zwnr0.pdf",
  "summary": "Here\u2019s the material information extracted from the ASX announcement, formatted concisely for trading/capital markets decisions:\n\n### **Key Highlights (Clinical Trial Results - ACCENT Study)**  \n- **Progression-Free Survival (PFS):** 7.6 months, a **2-month improvement** over chemotherapy alone (benchmark: 5.5 months in MPACT study).  \n- **Durability:** Mean **Days on Trial (DOT) of 202 days** vs. 117 days for chemotherapy alone.  \n- **Efficacy:**  \n  - **Objective Response Rate (ORR): 31%** (vs. 23% for chemotherapy).  \n  - **Disease Control Rate (DCR): 73%** (vs. 50% in MPACT).  \n  - Includes **1 Complete Response (CR)** and **1 pathological CR**.  \n- **Tolerability:** Adverse event profile similar to standard chemotherapy (gemcitabine/Abraxane), with negligible added burden.  \n\n### **Upcoming Catalysts**  \n- **Further ACCENT trial updates:** 2H 2025 (patient data) and **mature data expected Q1 2026**.  \n- **Phase 2b/3 pivotal trial planned for initiation in 2H 2026**.  \n- **AMPLICITY trial (US/Australia, FOLFIRINOX combo):** First patient dosing imminent.  \n\n### **Regulatory Status**  \n- **FDA Fast Track and Orphan Drug Designation** granted for pancreatic cancer.  \n\n**No capital raising, trading halt, or balance sheet updates identified.**  \n\n*Tailored for traders/investors: Focused on material efficacy data, trial milestones, and regulatory catalysts.*",
  "usage": {
    "prompt_tokens": 5411,
    "completion_tokens": 362,
    "total_tokens": 5773,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-05T22:58:16.076366"
}